Variable Annuity Life Insurance Co Updates Prospectus Fees
Variable Annuity Life Insurance Co Separate Account A updates its prospectus, changing key information on fees and expenses for investors.
Variable Annuity Life Insurance Co Updates Annuity Contracts
Variable Annuity Life Insurance Co Separate Account A updates its annuity contracts, impacting fees and expenses for investors.
Variable Annuity Life Insurance Co Updates Prospectus Fees
Variable Annuity Life Insurance Co Separate Account A updates its prospectus with new fee information that may impact investor decisions.
Variable Annuity Life Insurance Co Updates Prospectus Fees
Variable Annuity Life Insurance Co Separate Account A updates its prospectus, revealing new fees for its annuity contracts, impacting investors and the industry.
Variable Annuity Life Insurance Co Updates Prospectus Fees
Variable Annuity Life Insurance Co Separate Account A updates its prospectus, detailing changes in fees and expenses for its annuity contracts.
Innovator ETFs Trust Updates Prospectus for New ETF Offering
Innovator ETFs Trust updates its prospectus for the Innovator Equity Dual Directional 10 Buffer ETF, focusing on defined outcome strategies.
Innovator ETFs Trust Updates Prospectus for Defined Outcome ETF
Innovator ETFs Trust updates its prospectus for the Innovator Equity Defined Protection ETF, outlining strategies for the upcoming year.
Innovator ETFs Trust Files New Prospectus for ETF
Innovator ETFs Trust has filed a new prospectus for its Innovator Growth-100 Power Buffer ETF, marking a significant update for investors.
Variable Annuity Life Insurance Co Updates Annuity Fees
Variable Annuity Life Insurance Co Separate Account A updates its prospectus to reflect new fees and expenses for annuity contracts, impacting the investment landscape.
Innovator ETFs Trust Files New Prospectus for ETF Product
Innovator ETFs Trust updates its prospectus for the Innovator U.S. Equity Ultra Buffer ETF, emphasizing defined outcome strategies for investors.
Innovator ETFs Trust updates prospectus for equity buffer ETF
Innovator ETFs Trust has filed a new prospectus for its Innovator U.S. Equity Buffer ETF, effective November 2, 2026, reflecting its commitment to defined outcome strategies.
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Richard B. Handler, CEO of Jefferies Financial Group, reports stock transactions reflecting estate planning, as detailed in a recent SEC filing.
Brophy Michael Burkes sells 3,084 shares of Natera stock
Brophy Michael Burkes, CFO of Natera, Inc., sold 3,084 shares of common stock, signaling adjustments in executive holdings and compliance in the medical sector.
Glenbrook Capital Management Boosts Stake in SenesTech
Glenbrook Capital Management increases its stake in SenesTech, acquiring 30,000 shares, signaling confidence in the agricultural chemicals sector.
OS Therapies grants stock options to Chief Medical Officer
OS Therapies Inc grants stock options to CMO Robert Petit, highlighting its commitment to key personnel in the competitive pharmaceutical industry.
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Lin Yu-Hsin, CEO of Belite Bio, vests 5,000 shares after meeting performance criteria, highlighting executive compensation trends in the pharmaceutical sector.
Chen Wan-Shan Reports Share Transaction for Belite Bio
Chen Wan-Shan disclosed a transaction involving 13,796 shares of Belite Bio, reflecting active engagement in the pharmaceutical sector.
Clem Kerry M Reports 300,000 Stock Options in SEC Filing
Clem Kerry M, Chief Commercial Officer of OS Therapies, reports 300,000 stock options in SEC filing, highlighting executive incentives and growth potential.
OS Therapies grants stock options to director Craig Eagle
OS Therapies Inc grants 300,000 stock options to director Craig Eagle, signaling commitment to leadership incentives and aligning interests in the pharmaceutical industry.
OS Therapies grants stock options to CFO Francis Knuettel II
OS Therapies Inc has granted stock options to CFO Francis Knuettel II, highlighting its strategy to incentivize key executives in the pharmaceutical industry.